Table 1 Patient characteristics.

From: Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab

Patient characteristics

CT + B (N = 64) No. (%)

CT (N = 65) No. (%)

Median age, years (range)

69 (34–83)

67 (33–82)

Gender

 Male

40 (62.5)

35 (53.8)

 Female

24 (37.5)

30 (46.2)

Performance Status (ECOG)

 0

54 (84.4)

53 (81.5)

 1−2

10 (15.6)

12 (18.5)

Tumor localization

 Rectum

20 (31.2)

19 (29.2)

 Colon

44 (68.8)

46 (70.8)

 Right side

26# (41%)

24# (38%)

 Left side

37# (59%)

39# (62%)

Stage at diagnosis

 I–III

14 (21.9)

15 (23.1)

 IV

50 (78.1)

50 (76.9)

Grade

 1 + 2

32 (59.3)

34 (60.7)

 3

22 (40.7)

22 (39.3)

 Unknown/missing

10

9

CT regimen

 FOLFOX4

39 (60.9)

38 (58.5)

 FOLFIRI

25 (39.1)

27 (41.5)

KRAS status*

 Wild type

37 (59.7)

36 (60.0)

 Mutated

25 (40.3)

24 (40.0)

 Unknown/missing

2

5

Prior cancer therapy

 Surgery

51 (79.7)

48 (73.8)

 Radiotherapy

6 (9.4)

6 (9.2)

 Adjuvant chemotherapy

10 (15.6)

9 (13.8)

  1. CT, chemotherapy; B, bevacizumab.
  2. *Required by amendment no. 1 of 3rd May 2009; #Information about which side of the colon was involved was not available for one patient in the CT + B group and 2 patients in the CT group.
Back to article page